Regeneron, GlaxoSmithKline and Eli Lilly COVID-19 drugs prioritized for expedited review in Europe Altimmune ditches COVID-19 nasal spray vaccine, halts therapeutic enrollment after trial setbacks Moderna locks up Spikevax name in Europe, joins Pfizer's Comirnaty in wait for official brand approval in U.S. UPDATED Coronavirus tracker: Half of parents concerned about rare heart conditions following adolescent vaccination Roche and Atea's small, early data peek sees experimental COVID drug slash viral load in hospital patients Hospitals' volumes, margins recovery still lags behind early 2019 numbers, Kaufman Hall says Cambridge researchers pinpoint antimalarial, arthritis drugs for COVID-19 repurposing COVID-19 tracker: Britain preps for boosters later this year; Switzerland gives 4M AZ doses to COVAX Fujifilm's multibillion-dollar expansion spree rolls on with $850M capacity boost in U.S., U.K. Featured Story | By Kevin Dunleavy The European Union has identified COVID-19 treatments from Eli Lilly, Regeneron, Celltron and GSK/Vir for priority review in its attempt expedite approvals. The bloc hopes to have three antibody drugs endorsed by October. read more |
| |
|---|
|
| | Webinar: New Trends in Virtual Trials Monday, July 26 | 11am ET / 8am PT Last year, clinical trial platform developer Medable raised $91M in private funding, amid the COVID-19 pandemic that touched off huge demand among pharma companies looking to initiate “siteless” or virtual clinical trials. Explore the role of CROs in siteless trials and the opportunities and challenges for CROs to expand their capabilities in this burgeoning area. Register now. |
Top Stories By Kyle LaHucik After not-so-promising results from a phase 1 trial, Altimmune is scrapping its COVID-19 vaccine nasal spray candidate and stopping further enrollment in a COVID-19 therapeutic program. The news comes just as the Delta variant picks up steam around the world. read more By Beth Snyder Bulik Moderna has officially earned European Medicine Association approval for Spikevax as its COVID-19 vaccine brand name. Now, it joins Pfizer and BioNTech’s Comirnaty and AstraZeneca’s Vaxzevria, all with European name approvals, in awaiting a U.S. nod. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Ben Adams Infectious disease biotech and Fierce 15 winner Atea Pharmaceuticals alongside partner Roche have shown their antiviral can cut the viral load of SARS-CoV-02 in ill patients, though more data from a bigger trial will be needed to detail the level of success. read more By Dave Muoio With improvements over a pandemic year to be expected, the consulting group advised a comparison against pre-pandemic financials as a better metric of hospitals' financial recovery. read more By Angus Liu By using computational analyses, scientists at the University of Cambridge have identified 200 approved drugs as possible candidates for repurposing against COVID-19 and validated two of them in early tests. Given that both drugs are well-established, they should be rapidly advanced into clinical trials to test whether they can prevent or treat the virus, the researchers proposed. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner Britain is preparing to administer booster shots to its most vulnerable citizens, such as the elderly, as early as this September, Reuters reports. Switzerland said it will give 4 million AstraZeneca doses it had reserved to the vaccine sharing program COVAX, although it will keep its mRNA shots. And more headlines. read more By Fraiser Kansteiner Counting the latest investment, Fujifilm has blueprinted nearly $3 billion in manufacturing expansions since January, primarily in the U.S. The company will divvy up the latest $850 million infusion between operations in the U.K. and the U.S., where the company’s Texas and North Carolina plants are tackling manufacturing of Novavax’s late-stage pandemic vaccine, NVX-CoV2373. read more | | Webinar: COVID-19 Virus Sequencing for Drug Development Wednesday, July 28 | 10:30am ET / 7:30am PT As new COVID-19 variants continue to emerge, virus sequencing will play critical and ongoing role in drug and vaccine development. This webinar will connect insights from population surveillance to potential solutions for drug developers, outline approaches to COVID-19 virus sequencing and more. Register Now. |
|
